Navigation Links
Anti-tumor drugs tested by microfluidic device
Date:10/5/2010

ated.

Wu also said that, "Unlike conventional methods, the microfluidic device permits quantitative data to be obtained from individual cells; the device requires fewer numbers of cells and allows testing of amounts of reagents reduced by about 4 orders of magnitude. In a conventional 96-well plate study, each well is around 1 centimeter, while in our microchip device, each cell chamber has a dimension of hundreds of microns. Reducing the sample size has significant merit because in most cases, the biomolecules in use are extremely expensive, even in quantities in milligrams or less."

While this report concerns a test of five ladder channels on a single chip, higher throughputs should be possible, Wu stated. "This prototype system should be useful in the areas of biology and bioengineering, especially for discovering apoptosis-inducing agents," Wu concluded.


'/>"/>

Contact: Jason Bardi
jbardi@aip.org
301-209-3091
American Institute of Physics
Source:Eurekalert

0

GOOD

Page: 1 2

Related biology news :

1. Researchers identify new anti-tumor gene
2. Childrens National researchers develop novel anti-tumor vaccine
3. Iowa State, Ames Lab researchers identify structure that allows bacteria to resist drugs
4. White House policy advisor talks about legalized drugs
5. Ingredient in soap points toward new drugs for infection that affects 2 billion
6. Case Western Reserve researcher discovers new anti-pathogenic drugs to treat MRSA
7. Scripps scientists develop test providing new pathway for identifying obesity, diabetes drugs
8. U of M researchers identify 2 FDA approved drugs that may fight HIV
9. Scientists reveal new targets for anti-angiogenesis drugs
10. Drugs encased in nanoparticles travel to tumors on the surface of immune-system cells
11. Molecules delivering drugs as they walk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... "place" is increasingly being considered in the management ... new resource that can help them recognize and ... places in their lives. , Place-Based Conservation: ... co-edited by the Pacific Northwest Research Station,s Linda ... to conservation. The book is published by Springer ...
(Date:5/21/2013)... method for delivering molecules into single, targeted cells ... technique could find applications in drug delivery, cell ... a technique used to deliver molecules into ... that are caused by exposing them to electric ... cell transfection. (Cell transfection is the introduction of ...
(Date:5/21/2013)... University of Illinois at Chicago College of Medicine will study ... -- its main energy source -- and how changes in ... new $2 million, 4-year grant from the National Heart, Lung ... it uses fuel for energy. These changes may play a ... different in men and women, says E. Douglas Lewandowski, director ...
Breaking Biology News(10 mins):Single-cell transfection tool enables added control for biological studies 2Do men's and women's hearts burn fuel differently? 2
... raged over whether organic compounds and tiny globules of ... 84001 were processed by living creatures from the Red ... scrutiny ever since. Scientists at the Carnegie Institution's Geophysical ... how material associated with carbonate globules was created using ...
... more than 100 people have been infected with the H5N1 ... the fact that the virus does not spread easily from ... biomedical puzzle. , Now, a study of cells in the ... cells of the system that makes it difficult for the ...
... North America, two types of invasive vines are growing ... populations and bird habitats. , The vines are pale ... to stem the growth of and their steady conquest ... Canada, Cornell University is teaming up with the U.S. ...
Cached Biology News:Relic of life in that Martian meteorite? A fresh look 2Cell barrier shows why bird flu not so easily spread among humans 2Cell barrier shows why bird flu not so easily spread among humans 3CU, USDA team to curb two invasive, poisonous vines 2CU, USDA team to curb two invasive, poisonous vines 3
(Date:5/21/2013)... OXFORD, England , May 22, 2013 ... inhaled, novel drug-only formulation of glycopyrronium bromide designed using ... speciality pharmaceutical company developing a portfolio of inhaled ... 2 clinical study with PSX1002 that will assess its ... range of doses in patients with moderate to severe ...
(Date:5/21/2013)... study led by George Washington University Professor Tianshu ... ice in small droplets is strongly size-dependent, an ... nanoscale. The formation of ice at the nanoscale ... answer also has important implications for climate research ... ice from supercooled water is generally initiated by ...
(Date:5/21/2013)... Smarter Security, Inc., provider of premium, ... that Genzyme, a Sanofi company and leading biotech company, ... for a multi-use facility in the United States. With ... buildings, this latest order underscores the satisfaction and success ... device improving doorway access control. , “We ...
(Date:5/21/2013)... Md. , May 21, 2013  MacroGenics, ... 1 study of margetuximab (MGAH22), an Fc-modified chimeric ... tumors expressing the HER2 oncoprotein," will be presented ... Society of Clinical Oncology during the Developmental Therapeutics ... 3 at 4:15 – 4:30 PM.  The presentation ...
Breaking Biology Technology:Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4Study led by GW professor provides better understanding of water's freezing behavior at nanoscale 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
... A non-invasive blood,monitoring device that removes the need ... 2008 Kerrin Rennie Award for Excellence in Medical ... 24 September at the,Medical Technology Association of Australia ... CO-Oximeter from Masimo Corporation continuously,and non-invasively measures blood ...
... -, MONTVALE, N.J., Sept. 26 Memory,Pharmaceuticals Corp. ... completed,its Phase 1 multiple ascending dose study of R4996/MEM ... the fourth and final study,in the Company,s Phase 1 ... alpha-7 receptor being developed in collaboration with Roche.,Memory Pharmaceuticals ...
... a first, researchers at the University of Iowa and the ... cystic fibrosis (CF) that appears to closely mimic the disease ... the CF piglets and human newborns with CF suggest that ... and may also speed discovery of new treatments. The study ...
Cached Biology Technology:No Blood Needed Thanks to Innovative Medical Technology 2Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908 2Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908 3Researchers develop new model for cystic fibrosis 2
No description available in Ensembl. Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
12(S)-HETE-d8 is used as an internal standard for the quantification of 12(S)-HETE by stable isotope dilution mass spectrometry....
...
...
Biology Products: